| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18445 R78331 |
Lee (Controls exposed to SSRI), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: TCA only |
0.97 [0.80;1.19] C excluded (control group) |
194/613 472/1,465 | 666 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18410 R77732 |
Lee (Controls unexposed, general pop), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: TCA only | 1.00 [0.84;1.19] | 194/613 111,640/463,440 | 111,834 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11331 R41734 |
Solé, 2020 | C-section | during pregnancy (anytime or not specified) | nested case control | exposed to other treatment, sick | Adjustment: No Monotherapy: no or not specified | 1.00 [0.16;6.27] C | 2/5 38/95 | 40 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10931 R40646 |
Pastuszak (Controls exposed to Fluoxetine), 1993 | Caesarean section | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Matched Monotherapy: TCA only |
1.10 [0.41;2.95] C excluded (control group) |
11/43 10/42 | 21 | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10932 R40657 |
Pastuszak (Controls unexposed, NOS), 1993 | Caesarean section | 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: TCA only |
1.07 [0.40;2.86] C excluded (exposition period) |
11/43 10/41 | 21 | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.00 [0.84;1.19] | 111,874 | 618 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10931, 18445